title: Peroxisome proliferator-activated receptor-γ regulates inflammation and renin-angiotensin system activity in the hypothalamic paraventricular nucleus and ameliorates peripheral manifestations of heart failure.
abstract: Activation of peroxisome proliferator-activated receptor (PPAR)-γ, a nuclear transcription factor, has been shown to inhibit the production of proinflammatory cytokines and, in peripheral tissues, to downregulate the renin-angiotensin system. PPAR-γ is expressed in key brain areas involved in cardiovascular and autonomic regulation. We hypothesized that activation of central PPAR-γ would reduce sympathetic excitation and ameliorate peripheral manifestations of heart failure (HF) by inhibiting central inflammation and brain renin-angiotensin system activity. Two weeks after coronary artery ligation, HF rats received an intracerebroventricular infusion of the PPAR-γ agonist pioglitazone or vehicle for another 2 weeks. PPAR-γ expression in the paraventricular nucleus of hypothalamus, an important cardiovascular region, was unchanged in HF compared with sham-operated rats. However, PPAR-γ DNA binding activity was reduced, nuclear factor-κB activity was increased, and expression of proinflammatory cytokines and angiotensin II type-1 receptor was augmented in the HF rats. Mean blood pressure response to ganglionic blockade was greater; plasma norepinephrine levels, lung/body weight, right ventricle/body weight, and left ventricular end-diastolic pressure were increased; and maximal left ventricular dP/dt was decreased. All of these findings were ameliorated in HF rats treated with intracerebroventricular pioglitazone, which increased PPAR-γ expression and DNA binding activity in the paraventricular nucleus of hypothalamus. The results demonstrate that cardiovascular and autonomic mechanisms leading to heart failure after myocardial infarction can be modulated by activation of PPAR-γ in the brain. Central PPAR-γ may be a novel target for treatment of sympathetic excitation in myocardial infarction-induced HF.
authors.affiliation: Department of Internal Medicine, Veterans Affairs Medical Center, Iowa City, IA, USA.
authors.forename: Yang
authors.initials: Y
authors.lastname: Yu
authors.forename: Zhi-Hua
authors.initials: ZH
authors.lastname: Zhang
authors.forename: Shun-Guang
authors.initials: SG
authors.lastname: Wei
authors.forename: Robert M
authors.initials: RM
authors.lastname: Weiss
authors.forename: Robert B
authors.initials: RB
authors.lastname: Felder
mesh_terms: D000818:Animals; D001835:Body Weight / Q000502:physiology; D016207:Cytokines / Q000187:drug effects / Q000378:metabolism; D004435:Eating / Q000502:physiology; D006333:Heart Failure / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D007249:Inflammation / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D008297:Male; D023421:Models, Animal; D016328:NF-kappa B / Q000187:drug effects / Q000378:metabolism; D047495:PPAR gamma / Q000819:agonists / Q000502:physiology*; D010286:Paraventricular Hypothalamic Nucleus / Q000187:drug effects / Q000502:physiology*; D000077205:Pioglitazone; D051381:Rats; D017207:Rats, Sprague-Dawley; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology*; D045162:Thiazolidinediones / Q000494:pharmacology
chemical_list: D016207:Cytokines; D016328:NF-kappa B; D047495:PPAR gamma; D045162:Thiazolidinediones; D000077205:Pioglitazone
references.citation: Circ Res. 2000 Sep 29;87(7):596-602
references.pmid: 11009565
references.citation: Nature. 2010 Jul 22;466(7305):443-4
references.pmid: 20651677
references.citation: Am J Physiol Regul Integr Comp Physiol. 2003 Feb;284(2):R259-76
references.pmid: 12529279
references.citation: Circ Res. 2007 Aug 3;101(3):304-12
references.pmid: 17569888
references.citation: Circ Res. 2009 Jan 2;104(1):69-78
references.pmid: 19023129
references.citation: Cardiovasc Res. 2008 Sep 1;79(4):671-8
references.pmid: 18469338
references.citation: J Biol Chem. 2002 Feb 22;277(8):5719-24
references.pmid: 11600498
references.citation: Curr Opin Lipidol. 1997 Jun;8(3):159-66
references.pmid: 9211064
references.citation: Annu Rev Cell Biol. 1994;10:405-55
references.pmid: 7888182
references.citation: Circulation. 2000 Oct 10;102(15):1834-9
references.pmid: 11023940
references.citation: Circulation. 2009 Mar 3;119(8):1124-34
references.pmid: 19221220
references.citation: Circ Res. 2008 Sep 12;103(6):654-61
references.pmid: 18676352
references.citation: Braz J Med Biol Res. 2002 Sep;35(9):1017-23
references.pmid: 12219173
references.citation: Hypertension. 2008 Mar;51(3):727-33
references.pmid: 18227408
references.citation: Mol Cell Biochem. 2008 Oct;317(1-2):113-20
references.pmid: 18566752
references.citation: J Biol Chem. 1995 Jun 2;270(22):12953-6
references.pmid: 7768881
references.citation: J Hypertens. 2010 Jul;28(7):1488-97
references.pmid: 20410836
references.citation: Am J Physiol Heart Circ Physiol. 2011 Oct;301(4):H1559-69
references.pmid: 21803943
references.citation: Am J Physiol Heart Circ Physiol. 2009 Sep;297(3):H968-75
references.pmid: 19617416
references.citation: Hypertension. 2003 Oct;42(4):844-50
references.pmid: 12885795
references.citation: Hypertension. 2010 Jun;55(6):1444-53
references.pmid: 20404217
references.citation: J Biol Chem. 2003 Jul 25;278(30):28181-92
references.pmid: 12732648
references.citation: Clin Pharmacol Ther. 2009 Aug;86(2):216-20
references.pmid: 19553933
references.citation: Diabetes Res Clin Pract. 2005 Oct;70(1):53-62
references.pmid: 16002175
references.citation: Eur J Neurosci. 2005 Jul;22(1):278-82
references.pmid: 16029218
references.citation: Endocr J. 2010;57(10):847-52
references.pmid: 20890053
references.citation: Hypertension. 2008 Oct;52(4):708-14
references.pmid: 18768398
references.citation: Cardiovasc Drugs Ther. 2007 Feb;21(1):29-36
references.pmid: 17294127
references.citation: Trends Pharmacol Sci. 2007 May;28(5):244-9
references.pmid: 17416424
references.citation: Am J Physiol Heart Circ Physiol. 2003 Oct;285(4):H1650-9
references.pmid: 12969882
references.citation: J Cardiovasc Pharmacol. 2011 Nov;58(5):543-9
references.pmid: 21822148
references.citation: Circulation. 2009 Jun 23;119(24):3125-32
references.pmid: 19506106
references.citation: Nature. 2010 Jul 22;466(7305):451-6
references.pmid: 20651683
references.citation: Am J Physiol Heart Circ Physiol. 2009 Nov;297(5):H1557-66
references.pmid: 19717736
references.citation: Circ Res. 2010 Jun 11;106(11):1763-74
references.pmid: 20413786
references.citation: Hypertension. 1996 Apr;27(4):1009-17
references.pmid: 8613256
references.citation: Cell Mol Life Sci. 1999 Jun;55(6-7):932-43
references.pmid: 10412372
references.citation: J Immunol. 2009 Sep 1;183(5):3259-67
references.pmid: 19641141
references.citation: Blood. 2007 Dec 15;110(13):4373-84
references.pmid: 17785586
references.citation: Am J Physiol Heart Circ Physiol. 2010 May;298(5):H1546-55
references.pmid: 20173042
references.citation: Nature. 1998 Jan 1;391(6662):82-6
references.pmid: 9422509
references.citation: Int J Biochem Cell Biol. 2006;38(10):1654-61
references.pmid: 16713323
references.citation: Can J Physiol Pharmacol. 2009 Dec;87(12):979-88
references.pmid: 20029534
references.citation: Am J Physiol Regul Integr Comp Physiol. 2005 Sep;289(3):R633-41
references.pmid: 16105818
references.citation: J Cell Biochem. 2003 Nov 1;90(4):732-44
references.pmid: 14587029
references.citation: Endocrinology. 2009 Feb;150(2):707-12
references.pmid: 18845632
references.citation: Heart Fail Rev. 2000 Mar;5(1):73-86
references.pmid: 16228917
references.citation: Circulation. 2000 Mar 14;101(10):1165-71
references.pmid: 10715264
references.citation: Neuropharmacology. 2010 Feb;58(2):337-45
references.pmid: 19891980
references.citation: Hypertension. 2007 Mar;49(3):511-8
references.pmid: 17242297
references.citation: Endocr Pract. 2003 Sep-Oct;9(5):406-16
references.pmid: 14583425
references.citation: Hypertension. 2008 Aug;52(2):342-50
references.pmid: 18574076
references.citation: Nat Med. 2011 May;17(5):623-6
references.pmid: 21532595
references.citation: Am J Physiol Regul Integr Comp Physiol. 2008 Nov;295(5):R1539-45
references.pmid: 18753266
references.citation: Am J Physiol Regul Integr Comp Physiol. 2002 Aug;283(2):R281-3
references.pmid: 12121837
references.citation: Hypertension. 2006 Jan;47(1):102-8
references.pmid: 16344371
references.citation: Front Biosci. 2008 Jan 01;13:1813-26
references.pmid: 17981670
references.citation: Front Neuroendocrinol. 1997 Jul;18(3):292-353
references.pmid: 9237080
references.citation: Expert Opin Drug Saf. 2009 Jan;8(1):15-32
references.pmid: 19236215
references.citation: Am J Physiol Regul Integr Comp Physiol. 2009 Jan;296(1):R1-8
references.pmid: 18971355
references.citation: Front Aging Neurosci. 2010 May 21;2:
references.pmid: 20725514
references.citation: Hypertension. 2010 Aug;56(2):297-303
references.pmid: 20547972